If you have hypertrophic cardiomyopathy (HCM) and are experiencing symptoms such as shortness of breath, chest pain, ...

Ethosuximide does not demonstrate efficacy over placebo for the treatment of irritable bowel syndrome-related abdominal pain and has limited tolerability.

Medications such as metformin, DPP-4 inhibitors, SGLT-2 inhibitors, GLP-1 receptor agonists, or insulin may be prescribed ...

A new study published in the Journal of American Medical Association showed that Ethosuximide was linked to decreased ...

Novamigra Therapeutics secures ~€3 million funding to advance first-in-human Phase 1 study of its migraine prophylaxis ...

Existing treatments for other conditions show potential for use in managing type 1 diabetes, a recent scientific conference heard ...

Detailed price information for Milestone Pharmaceuticals Inc (MIST-Q) from The Globe and Mail including charting and trades.

Milestone Pharmaceuticals, a Canadian company with a U.S. subsidiary in Charlotte, is starting the new year with its first ...

HAVE you set any New Year’s resolutions? January is full of promises to “start again”, which may fill you with hope or dread.

As of Friday, January 09, Milestone Pharmaceuticals Inc.’s MIST share price has dipped by 5.84%, which has investors ...

ESTEVE and TerSera Therapeutics LLC announced today that they have entered into an agreement in which ESTEVE will acquire ...

While researchers caution it's not a "one-size-fits-all solution," the news could be helpful for certain Americans.